Study results from the Clinical Trials Network's first 10 years: where do they lead?
about
Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependenceGender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findingsRelation of study design to recruitment and retention in CTN trials.The Appalachian Tri-State Node Experiences with the National Institute on Drug Abuse Clinical Trials Network.Direct-to-Consumer Marketing: A Complementary Approach to Traditional Dissemination and implementation Efforts for Mental Health and Substance Abuse Interventions.Evaluating whether direct-to-consumer marketing can increase demand for evidence-based practice among parents of adolescents with substance use disorders: rationale and protocol.Ten take home lessons from the first 10 years of the CTN and 10 recommendations for the futureRates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials.Re-envisioning Addiction Treatment: A Six-Point Plan.Selection and utilization of assessment instruments in substance abuse treatment trials: the National Drug Abuse Treatment Clinical Trials Network experience.Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.Perceptions of 'Evidence-Based Practice' among the Consumers of Adolescent Substance Use TreatmentThe National Drug Abuse Treatment Clinical Trials Network: forging a partnership between research knowledge and community practice.Addiction treatment trials: how gender, race/ethnicity, and age relate to ongoing participation and retention in clinical trials.The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatmentStrategies for safety reporting in substance abuse trials.Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.Pioglitazone, a PPARγ agonist, reduces nicotine craving in humans, with marginal effects on abuse potential.Complexities with group therapy facilitation in substance use disorder specialty treatment settings.Beyond Abstinence: Changes in Indices of Quality of Life with Time in Recovery in a Nationally Representative Sample of U.S. Adults.
P2860
Q30579736-A2C5C955-4AD7-4725-9A3A-74CC8D6791D9Q33776944-FA8FFABE-1A9C-458E-B9CE-BF494F5D7C05Q33783250-45C448AD-5B82-469B-B429-43B60AA36DC0Q35178476-E870B034-A4A8-4B31-AF77-CA8D2660A136Q35215651-04CC2070-5318-44D2-9C5F-782FC30EB4A5Q35552994-F95697E7-072C-4C34-8A75-2B9C35F63AD3Q35558358-AB6BDDFC-D4A0-4F3A-A83C-9DD1F23CA436Q35575816-6D817E4B-9D03-425C-8D88-EBC8AFAC12F9Q35598143-DECB76A6-0FA4-47DD-84A6-83F16D4AF5CBQ35717934-1AAF17C9-8E14-4CD9-B13A-450FBA04C9D8Q36048088-EABE873A-3E02-438F-8B7F-14C13875EB81Q36165376-3A1FBADB-001B-4B67-9DEE-C84775C1EE96Q36510797-032DBD8F-744B-4E9D-BFC9-5D19DF28189EQ36795023-EB0A2440-4188-41C1-B8C1-A5F0B08FA103Q37355266-3628BD4F-B98D-4E40-9FBB-4F252EED62EAQ37355663-85BA402A-CC54-4777-8BF3-6433342307A6Q37419480-8DA6D7CB-7FC6-4EB4-9EAD-681F6853225EQ37919885-82D2065F-392F-44A4-835B-4C25DB62AC0DQ38815839-3F5D8B20-0ACD-41E7-8D4F-BB35904CADF8Q50094674-D64DCA39-4046-474D-AE5D-0AD04C525C0CQ52335191-21B91035-1F37-449C-BFEF-9F50BA216E3FQ52688530-7AF1EE98-5AD9-4C31-AD70-6BBF1219B9F2
P2860
Study results from the Clinical Trials Network's first 10 years: where do they lead?
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@ast
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@en
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@nl
type
label
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@ast
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@en
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@nl
prefLabel
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@ast
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@en
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@nl
P2093
P2860
P1476
Study results from the Clinical Trials Network's first 10 years: where do they lead?
@en
P2093
Andrew J Saxon
Donald A Calsyn
Elizabeth A Wells
Thomas R Jackson
P2860
P304
P356
10.1016/J.JSAT.2009.12.009
P478
38 Suppl 1
P577
2010-06-01T00:00:00Z